Burzynski Research Institute, Inc. (BZYR)
USD 0.04
(0.0%)
USD 0.04
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -1.33 Million USD | -45.74% |
| 2023 | -916.29 Thousand USD | 6.18% |
| 2022 | -976.65 Thousand USD | 24.97% |
| 2021 | -1.3 Million USD | 20.38% |
| 2020 | -1.63 Million USD | 0.17% |
| 2019 | -1.63 Million USD | -1.53% |
| 2018 | -1.61 Million USD | -7.2% |
| 2017 | -1.5 Million USD | 24.96% |
| 2016 | -2 Million USD | 30.67% |
| 2015 | -2.89 Million USD | 32.3% |
| 2014 | -4.27 Million USD | 34.27% |
| 2013 | -6.49 Million USD | 9.2% |
| 2012 | -7.15 Million USD | -42.26% |
| 2011 | -5.03 Million USD | -4.15% |
| 2010 | -4.83 Million USD | 5.78% |
| 2009 | -5.12 Million USD | -13.38% |
| 2008 | -4.52 Million USD | -5.1% |
| 2007 | -4.3 Million USD | 7.56% |
| 2006 | -4.65 Million USD | 6.27% |
| 2005 | -4.96 Million USD | -13.26% |
| 2004 | -4.38 Million USD | 0.81% |
| 2003 | -4.42 Million USD | 14.6% |
| 2002 | -5.17 Million USD | -12.74% |
| 2001 | -4.59 Million USD | -5.09% |
| 2000 | -4.36 Million USD | 12.9% |
| 1999 | -5.01 Million USD | 29.4% |
| 1998 | -7.1 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 FY | -1.33 Million USD | -45.74% |
| 2024 Q4 | -362.9 Thousand USD | 16.19% |
| 2024 Q3 | -433.01 Thousand USD | -71.76% |
| 2024 Q2 | -252.1 Thousand USD | 12.28% |
| 2024 Q1 | -287.4 Thousand USD | -33.06% |
| 2023 Q2 | -215.91 Thousand USD | 6.83% |
| 2023 FY | -916.29 Thousand USD | 6.18% |
| 2023 Q4 | -215.99 Thousand USD | 14.5% |
| 2023 Q3 | -252.63 Thousand USD | -17.01% |
| 2023 Q1 | -231.73 Thousand USD | -35.61% |
| 2022 Q3 | -264.77 Thousand USD | -17.83% |
| 2022 Q1 | -316.28 Thousand USD | -26.04% |
| 2022 FY | -976.65 Thousand USD | 24.97% |
| 2022 Q4 | -170.87 Thousand USD | 35.46% |
| 2022 Q2 | -224.71 Thousand USD | 28.95% |
| 2021 Q3 | -264.32 Thousand USD | 19.55% |
| 2021 Q1 | -457.97 Thousand USD | -60.83% |
| 2021 Q4 | -250.93 Thousand USD | 5.07% |
| 2021 FY | -1.3 Million USD | 20.38% |
| 2021 Q2 | -328.54 Thousand USD | 28.26% |
| 2020 Q1 | -468.31 Thousand USD | -38.21% |
| 2020 Q4 | -284.75 Thousand USD | 39.63% |
| 2020 FY | -1.63 Million USD | 0.17% |
| 2020 Q2 | -410.22 Thousand USD | 12.4% |
| 2020 Q3 | -471.69 Thousand USD | -14.99% |
| 2019 Q4 | -338.83 Thousand USD | 22.93% |
| 2019 Q3 | -439.63 Thousand USD | 2.23% |
| 2019 FY | -1.63 Million USD | -1.53% |
| 2019 Q1 | -409.57 Thousand USD | -26.41% |
| 2019 Q2 | -449.67 Thousand USD | -9.79% |
| 2018 Q2 | -425.74 Thousand USD | 7.89% |
| 2018 FY | -1.61 Million USD | -7.2% |
| 2018 Q1 | -462.21 Thousand USD | -32.13% |
| 2018 Q3 | -401.12 Thousand USD | 5.78% |
| 2018 Q4 | -324.01 Thousand USD | 19.22% |
| 2017 FY | -1.5 Million USD | 24.96% |
| 2017 Q1 | -369.95 Thousand USD | 9.79% |
| 2017 Q3 | -383.13 Thousand USD | 4.65% |
| 2017 Q4 | -349.81 Thousand USD | 8.7% |
| 2017 Q2 | -401.81 Thousand USD | -8.61% |
| 2016 Q3 | -460.19 Thousand USD | 9.82% |
| 2016 Q1 | -624.52 Thousand USD | -1.24% |
| 2016 Q4 | -410.08 Thousand USD | 10.89% |
| 2016 FY | -2 Million USD | 30.67% |
| 2016 Q2 | -510.3 Thousand USD | 18.29% |
| 2015 FY | -2.89 Million USD | 32.3% |
| 2015 Q1 | -840.88 Thousand USD | -1.88% |
| 2015 Q4 | -616.88 Thousand USD | 12.83% |
| 2015 Q3 | -707.64 Thousand USD | 2.62% |
| 2015 Q2 | -726.69 Thousand USD | 13.58% |
| 2014 Q4 | -825.36 Thousand USD | 16.03% |
| 2014 Q2 | -1.1 Million USD | 18.46% |
| 2014 Q3 | -982.86 Thousand USD | 11.17% |
| 2014 FY | -4.27 Million USD | 34.27% |
| 2014 Q1 | -1.35 Million USD | 9.23% |
| 2013 Q4 | -1.49 Million USD | 2.27% |
| 2013 Q1 | -1.68 Million USD | 17.31% |
| 2013 Q2 | -1.79 Million USD | -6.79% |
| 2013 FY | -6.49 Million USD | 9.2% |
| 2013 Q3 | -1.52 Million USD | 14.74% |
| 2012 Q2 | -1.78 Million USD | -18.93% |
| 2012 FY | -7.15 Million USD | -42.26% |
| 2012 Q3 | -1.83 Million USD | -3.08% |
| 2012 Q4 | -2.03 Million USD | -10.42% |
| 2012 Q1 | -1.5 Million USD | -20.88% |
| 2011 Q4 | -1.24 Million USD | -2.65% |
| 2011 Q3 | -1.2 Million USD | -0.43% |
| 2011 Q1 | -1.37 Million USD | -5.13% |
| 2011 Q2 | -1.2 Million USD | 12.42% |
| 2011 FY | -5.03 Million USD | -4.15% |
| 2010 Q4 | -1.3 Million USD | -8.21% |
| 2010 Q2 | -1.19 Million USD | -6.78% |
| 2010 FY | -4.83 Million USD | 5.78% |
| 2010 Q1 | -1.11 Million USD | 7.97% |
| 2010 Q3 | -1.2 Million USD | -1.19% |
| 2009 Q3 | -1.34 Million USD | -4.01% |
| 2009 FY | -5.12 Million USD | -13.38% |
| 2009 Q1 | -1.28 Million USD | -0.27% |
| 2009 Q2 | -1.29 Million USD | -0.64% |
| 2009 Q4 | -1.21 Million USD | 9.42% |
| 2008 FY | -4.52 Million USD | -5.1% |
| 2008 Q4 | -1.27 Million USD | -24.22% |
| 2008 Q3 | -1.02 Million USD | 10.73% |
| 2008 Q1 | -1.06 Million USD | -2.0% |
| 2008 Q2 | -1.15 Million USD | -8.67% |
| 2007 Q1 | -1.15 Million USD | -8.11% |
| 2007 Q4 | -1.04 Million USD | -8.48% |
| 2007 Q3 | -958.92 Thousand USD | 16.33% |
| 2007 Q2 | -1.14 Million USD | 0.98% |
| 2007 FY | -4.3 Million USD | 7.56% |
| 2006 Q1 | -1.18 Million USD | 8.93% |
| 2006 Q2 | -1.3 Million USD | -10.51% |
| 2006 Q3 | -1.09 Million USD | 16.43% |
| 2006 Q4 | -1.07 Million USD | 2.04% |
| 2006 FY | -4.65 Million USD | 6.27% |
| 2005 Q2 | -1.21 Million USD | 6.25% |
| 2005 Q4 | -1.29 Million USD | -11.89% |
| 2005 Q3 | -1.16 Million USD | 4.2% |
| 2005 Q1 | -1.29 Million USD | -0.12% |
| 2005 FY | -4.96 Million USD | -13.26% |
| 2004 FY | -4.38 Million USD | 0.81% |
| 2004 Q1 | -1.06 Million USD | 12.7% |
| 2004 Q2 | -1.13 Million USD | -7.06% |
| 2004 Q3 | -888.16 Thousand USD | 22.09% |
| 2004 Q4 | -1.29 Million USD | -45.39% |
| 2003 Q3 | -1.1 Million USD | -9.21% |
| 2003 FY | -4.42 Million USD | 14.6% |
| 2003 Q1 | -1.07 Million USD | 11.79% |
| 2003 Q2 | -1.01 Million USD | 5.72% |
| 2003 Q4 | -1.21 Million USD | -10.02% |
| 2002 FY | -5.17 Million USD | -12.74% |
| 2002 Q4 | -1.22 Million USD | -0.07% |
| 2002 Q1 | -1.41 Million USD | -28.19% |
| 2002 Q2 | -1.31 Million USD | 6.88% |
| 2002 Q3 | -1.21 Million USD | 7.42% |
| 2001 Q4 | -1.1 Million USD | 8.92% |
| 2001 Q2 | -1.19 Million USD | -10.17% |
| 2001 Q1 | -1.08 Million USD | -4.51% |
| 2001 FY | -4.59 Million USD | -5.09% |
| 2001 Q3 | -1.21 Million USD | -1.6% |
| 2000 Q4 | -1.03 Million USD | -7.14% |
| 2000 FY | -4.36 Million USD | 12.9% |
| 2000 Q1 | -1.29 Million USD | 0.0% |
| 2000 Q2 | -1.07 Million USD | 17.23% |
| 2000 Q3 | -966.85 Thousand USD | 9.75% |
| 1999 FY | -5.01 Million USD | 29.4% |
| 1998 FY | -7.1 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HST Global, Inc. | -140.9 Thousand USD | -847.739% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -94.4% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -678.634% |
| CytoDyn Inc. | -18.05 Million USD | 92.605% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 97.736% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| MultiCell Technologies, Inc. | -722.81 USD | -184655.468% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 26.476% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 73.527% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -4358.57% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -635.835% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Alpha Cognition Inc. | -9.7 Million USD | 86.241% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 97.594% |
| SQZ Biotechnologies Company | -75.82 Million USD | 98.239% |
| Resverlogix Corp. | -12.74 Million USD | 89.525% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -242.796% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 113.707% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 45.611% |
| Mesoblast Limited | -84.14 Million USD | 98.413% |
| GB Sciences, Inc. | -1.42 Million USD | 5.989% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -94.4% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 92.517% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 60.78% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 79.912% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 57.85% |
| ContraFect Corporation | -56.88 Million USD | 97.653% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 51.454% |
| BioStem Technologies, Inc. | -7.77 Million USD | 82.833% |
| LadRx Corporation | -3.82 Million USD | 65.074% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 91.585% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -19.341% |
| CSL Limited | 3.7 Billion USD | 100.036% |
| Biomind Labs Inc. | -1 Million USD | -32.273% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -43.382% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 101.632% |
| Nascent Biotech, Inc. | -2.22 Million USD | 40.112% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 98.14% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 127.172% |
| GeneThera, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 137.724% |
| Adynxx, Inc. | - USD | Infinity% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 13.061% |
| Marizyme, Inc. | -34.08 Million USD | 96.082% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 84.007% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -136.475% |
| Zenith Capital Corp. | -8.94 Million USD | 85.067% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 53.151% |
| Halberd Corporation | -75.05 Thousand USD | -1679.388% |
| Genus plc | 6.4 Million USD | 120.866% |
| Pharming Group N.V. | -4.87 Million USD | 72.632% |
| MetaStat, Inc. | - USD | Infinity% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 32.774% |
| IMV Inc. | -38.67 Million USD | 96.547% |
| Affymax, Inc. | -15.04 Million USD | 91.124% |
| SYBLEU INC | -149.18 Thousand USD | -795.181% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -27.915% |
| Enzolytics Inc. | -2.14 Million USD | 37.852% |
| argenx SE | -425.04 Million USD | 99.686% |
| AVAX Technologies, Inc. | 6.69 Million USD | 119.953% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 4.748% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | 64.354% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -5205.646% |
| Cell Source, Inc. | -4.32 Million USD | 69.125% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -176.451% |
| Q BioMed Inc. | -3.44 Million USD | 61.243% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 68.492% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -6.324% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 49.175% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 70.68% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 97.571% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 53.97% |
| Rebus Holdings, Inc. | -664 Thousand USD | -101.119% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -35.707% |
| Skye Bioscience, Inc. | -13.67 Million USD | 90.232% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 28.371% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 33.387% |
| ONE Bio Corp. | 13.68 Million USD | 109.761% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 30.9% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -18.715% |
| Agentix Corp. | -1.37 Million USD | 2.648% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 54.257% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 15.445% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -7565.639% |
| Kadimastem Ltd | -3.04 Million USD | 56.075% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -410.24% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -221.42% |
| NovAccess Global Inc. | -2.46 Million USD | 45.863% |
| Itoco Inc. | -919.14 Thousand USD | -45.291% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -506.799% |
| Qrons Inc. | -643.67 Thousand USD | -107.469% |
| Mobile Lads Corp. | -554.55 Thousand USD | -140.813% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.679% |
| International Stem Cell Corporation | -663 Thousand USD | -101.422% |
| Bioxytran, Inc. | -3.82 Million USD | 65.042% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -2436.913% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -6465.541% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 96.318% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 17.464% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -81.485% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 57.074% |
| Neutra Corp. | -229.48 Thousand USD | -481.923% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 92.386% |
| PureTech Health plc | -146.19 Million USD | 99.087% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 93.786% |
| IXICO plc | -1.43 Million USD | 7.068% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 85.93% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 98.904% |
| CSL Limited | 3.81 Billion USD | 100.035% |
| Cellectis S.A. | -108.85 Million USD | 98.773% |